Capricor Therapeutics (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders.
CAPR’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. The HOPE-Duchenne trial was funded in part by the California Institute for Regenerative Medicine.
CAPR is one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
The company was founded in 2005 and is headquartered in Beverly Hills, California.
September 26, 2017
RegMed Investors’ (RMi) pre-open indications; the sector optic isn’t that good but …
September 25, 2017
RegMed Investors’ (RMi) closing bell; be careful for the upside you’ve wished for
September 25, 2017
RegMed Investors’ (RMi) pre-open indications; there is a season (turn, turn, turn) and a time to every purpose, under heaven
September 22, 2017
RegMed Investors’ (RMi) closing bell; sector gets downsized again
September 22, 2017
RegMed Investors’ (RMi) pre-open indications; pricing hunkers down
September 21, 2017
RegMed Investors’ (RMi) closing bell; bowling for strikes, it’s all in the approach
September 21, 2017
RegMed Investors’ (RMi) pre-open indications; there exists a fundamental mistrust
September 20, 2017
RegMed Investors’ (RMi) closing bell; shareholder populism is on the rise and companies better adapt
September 20, 2017
RegMed Investors’ (RMi) pre-open indications; who is “our” rocket man or woman CEO
September 19, 2017
RegMed Investors’ (RMi) closing bell; the sector is running out of powder
35 companies, 1 interpreter!
Insight, foresight and recommendation
Capricor (CAPR) --January started out at $1.57 with a high of $1.70 beginning February at $1.83. a high of $2.00 on 2/15 dropping to $1.85 on 2/16 … CAPR desperately NEEDS to re-finance, be ready for depreciation and dilution -
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.